Clinical trial
A Phase 2 Study of Outpatient Epcoritamab in Large B-cell Lymphoma
NCT06811272 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Study of Outpatient Epcoritamab in Large B-cell Lymphoma
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- June 5, 2025
- Completion date
- October 1, 2028
- Enrollment
- 40 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
refractory large b-cell lymphoma, relapsed large b-cell lymphoma